Jinhai Medical Technology Limited

SEHK:2225 Stock Report

Market Cap: HK$8.8b

Jinhai Medical Technology Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Zhenfei Wang

Chief executive officer

S$111.0k

Total compensation

CEO salary percentage97.3%
CEO tenure5.4yrs
CEO ownershipn/a
Management average tenure1.2yrs
Board average tenure5.4yrs

Recent management updates

The CEO Of Jinhai Medical Technology Limited (HKG:2225) Might See A Pay Rise On The Horizon

Jun 19
The CEO Of Jinhai Medical Technology Limited (HKG:2225) Might See A Pay Rise On The Horizon

Recent updates

Jinhai Medical Technology Limited's (HKG:2225) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Dec 16
Jinhai Medical Technology Limited's (HKG:2225) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Jinhai Medical Technology (HKG:2225) Has Debt But No Earnings; Should You Worry?

Nov 05
Jinhai Medical Technology (HKG:2225) Has Debt But No Earnings; Should You Worry?

Why We're Not Concerned About Jinhai Medical Technology Limited's (HKG:2225) Share Price

Oct 06
Why We're Not Concerned About Jinhai Medical Technology Limited's (HKG:2225) Share Price

The CEO Of Jinhai Medical Technology Limited (HKG:2225) Might See A Pay Rise On The Horizon

Jun 19
The CEO Of Jinhai Medical Technology Limited (HKG:2225) Might See A Pay Rise On The Horizon

Investors Appear Satisfied With Jinhai Medical Technology Limited's (HKG:2225) Prospects As Shares Rocket 26%

May 13
Investors Appear Satisfied With Jinhai Medical Technology Limited's (HKG:2225) Prospects As Shares Rocket 26%

Subdued Growth No Barrier To Jinhai Medical Technology Limited (HKG:2225) With Shares Advancing 31%

Mar 17
Subdued Growth No Barrier To Jinhai Medical Technology Limited (HKG:2225) With Shares Advancing 31%

What Jinhai International Group Holdings Limited's (HKG:2225) 50% Share Price Gain Is Not Telling You

Jan 31
What Jinhai International Group Holdings Limited's (HKG:2225) 50% Share Price Gain Is Not Telling You

Here's What's Concerning About Jinhai International Group Holdings' (HKG:2225) Returns On Capital

Jun 06
Here's What's Concerning About Jinhai International Group Holdings' (HKG:2225) Returns On Capital

Be Wary Of Jinhai International Group Holdings (HKG:2225) And Its Returns On Capital

Mar 07
Be Wary Of Jinhai International Group Holdings (HKG:2225) And Its Returns On Capital

CEO Compensation Analysis

How has Zhenfei Wang's remuneration changed compared to Jinhai Medical Technology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-S$10m

Mar 31 2024n/an/a

-S$7m

Dec 31 2023S$111kS$108k

-S$3m

Sep 30 2023n/an/a

-S$2m

Jun 30 2023n/an/a

S$6k

Mar 31 2023n/an/a

S$237k

Dec 31 2022S$240kS$237k

S$468k

Sep 30 2022n/an/a

S$443k

Jun 30 2022n/an/a

S$419k

Mar 31 2022n/an/a

S$86k

Dec 31 2021S$356kS$353k

-S$246k

Sep 30 2021n/an/a

S$320k

Jun 30 2021n/an/a

S$852k

Mar 31 2021n/an/a

S$1m

Dec 31 2020S$365kS$362k

S$1m

Sep 30 2020n/an/a

S$516k

Jun 30 2020n/an/a

-S$231k

Mar 31 2020n/an/a

-S$459k

Dec 31 2019S$362kS$161k

-S$686k

Compensation vs Market: Zhenfei's total compensation ($USD82.02K) is below average for companies of similar size in the Hong Kong market ($USD478.99K).

Compensation vs Earnings: Zhenfei's compensation has been consistent with company performance over the past year.


CEO

Zhenfei Wang (43 yo)

5.4yrs

Tenure

S$111,000

Compensation

Mr. Zhenfei Wang has been Chief Executive Officer and Executive Director of Jinhai Medical Technology Limited (formerly known as Jinhai International Group Holdings Limited) (formerly known as Kakiko Group...


Leadership Team

NamePositionTenureCompensationOwnership
Guobao Chen
Executive Chairman of the Board5.4yrsS$337.00k48.94%
HK$ 4.3b
Zhenfei Wang
CEO & Executive Director5.4yrsS$111.00kno data
Yunping Li
Executive Director1.4yrsS$86.00kno data
Man Yiu Wong
Chief Financial Officer5.1yrsno datano data
Yong Dai
COO & Executive Directorless than a yearno datano data
Lei Liu
Chief Technical Officerless than a yearno datano data
Xiao He
Chief Marketing Officerless than a yearno datano data
Yuen Cheng
Company Secretaryless than a yearno datano data

1.2yrs

Average Tenure

51yo

Average Age

Experienced Management: 2225's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Guobao Chen
Executive Chairman of the Board5.4yrsS$337.00k48.94%
HK$ 4.3b
Zhenfei Wang
CEO & Executive Director5.4yrsS$111.00kno data
Yunping Li
Executive Director5.4yrsS$86.00kno data
Yong Dai
COO & Executive Directorless than a yearno datano data
Huasheng Wang
Non-Executive Director5.4yrsS$33.00kno data
Jianjun Yan
Independent Non-Executive Director5.4yrsS$21.00kno data
Yimin Fan
Independent Non-Executive Director5.4yrsS$21.00kno data
Meihua Yang
Independent Non-Executive Director2.9yrsS$21.00kno data

5.4yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 2225's board of directors are considered experienced (5.4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 01:19
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jinhai Medical Technology Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution